Havemeyer Place LP Acquires New Stake in Globus Medical, Inc. $GMED

Havemeyer Place LP acquired a new stake in shares of Globus Medical, Inc. (NYSE:GMED) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,204 shares of the medical device company’s stock, valued at approximately $1,327,000.

A number of other hedge funds also recently bought and sold shares of the company. Parallel Advisors LLC increased its position in Globus Medical by 95.5% during the fourth quarter. Parallel Advisors LLC now owns 1,089 shares of the medical device company’s stock valued at $95,000 after acquiring an additional 532 shares during the last quarter. Vise Technologies Inc. purchased a new stake in Globus Medical in the fourth quarter worth about $739,000. Globeflex Capital L P purchased a new stake in Globus Medical in the fourth quarter worth about $173,000. Daiwa Securities Group Inc. increased its position in Globus Medical by 4.3% in the fourth quarter. Daiwa Securities Group Inc. now owns 6,597 shares of the medical device company’s stock worth $576,000 after buying an additional 275 shares in the last quarter. Finally, Cibc World Market Inc. purchased a new stake in Globus Medical in the fourth quarter worth about $482,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings restated a “hold (c+)” rating on shares of Globus Medical in a research report on Wednesday, April 15th. Needham & Company LLC upped their price target on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Truist Financial set a $115.00 price target on Globus Medical in a research report on Wednesday, February 25th. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Stock Up 0.2%

NYSE GMED opened at $80.13 on Monday. The firm has a market cap of $10.88 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 1.65 and a beta of 0.95. The business has a 50-day moving average price of $86.27 and a 200-day moving average price of $88.25. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The business’s quarterly revenue was up 27.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Research analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.